| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 10211568 | Journal of Stroke and Cerebrovascular Diseases | 2018 | 7 Pages |
Abstract
Our results suggest that even at therapeutic plasma concentrations, rivaroxaban may increase the risk of HT after thrombolysis in some conditions, such as hypertension and/or a prolonged ischemic period.
Related Topics
Health Sciences
Medicine and Dentistry
Clinical Neurology
Authors
Hiroshi MD, Fumiaki MD, PhD, Hideyuki MD, PhD, Takao PhD, Eiichi MD, PhD, Sadahiro MD, PhD, Michiyasu MD, PhD,